Nervamat (Ropinirole Hydrochloride)

Ropinirole hydrochloride, the active ingredient in Nervamat, is a dopamine agonist presented as an oral dosage form for oral use. It is used to treat motor symptoms in Parkinson's disease and to relieve symptoms of restless legs syndrome in adult patients. GNH USA supplies Nervamat as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ropinirole acts on dopaminergic pathways and is indicated for movement‑disorder conditions. - Parkinson's disease: improves motor control and reduces tremor, rigidity, and bradykinesia. - Restless legs syndrome: decreases uncomfortable leg sensations and the urge to move, improving sleep quality.

Ropinirole may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Dizziness: sensation of light‑headedness, especially on standing. - Somnolence: increased sleepiness during the day. - Headache: mild to moderate head pain.

Serious or Rare Side Effects: - Hallucinations: visual or auditory disturbances. - Impulse control disorders: compulsive gambling, shopping, or eating. - Severe hypotension: sudden drop in blood pressure leading to fainting.

When prescribing ropinirole, clinicians should consider several safety measures. - Dose titration: start with a low dose and increase gradually to minimize side effects. - Cardiovascular disease: monitor blood pressure and heart rate regularly. - Psychiatric history: watch for emergence of hallucinations or mood changes. - Renal impairment: adjust dose in patients with reduced kidney function. - Pregnancy: use only if the potential benefit justifies the potential risk to the fetus. - Store at room temperature: keep in the original container, protect from moisture and light.

Ropinirole can interact with other medicines, altering its effectiveness or safety.

Major Interactions (Avoid): - MAO‑B inhibitors: may cause hypertensive crisis when combined. - Antipsychotics that block dopamine receptors: can reduce ropinirole’s therapeutic effect.

Moderate Interactions (Monitor Closely): - CYP1A2 inhibitors (e.g., fluvoxamine): increase ropinirole plasma levels. - CYP1A2 inducers (e.g., smoking): decrease ropinirole plasma levels. - Alcohol: may enhance sedative effects and dizziness.